Features

What are the key issues on the bio/pharmaceutical industry’s radar in 2026? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.

Does your company have major company news that it would like to share at DCAT Week? DCAT Member Companies are invited to apply to present at the Member Company Announcement Forum, a valuable platform in which senior executives make significant news announcements.

As 2025 comes to a close, what were the key developments—expansions and M&A—from CDMOs/CMOs this year? DCAT Value Chain Insights looks at the companies and moves that topped the headlines this year.

The European Commission, the European Parliament, and the Council of the European Union, have agreed to a proposal for the EU’s landmark pharma legislation, setting the stage for major reforms.

Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?

The UK and the US governments have agreed in principle on drug pricing and tariffs/trade on pharmaceuticals between the two countries, months after the countries formed an initial trade pact. What is the new deal and the impact on pharma?

Innovation is central to the bio/pharma industry, so what have been the key developments in 2025? Which companies and their innovation stand out? DCAT Value Chain Insights takes an inside look.

What has been the impact of US tariffs thus far on global trade, including on pharmaceuticals and pharmaceutical ingredients? Plus, Switzerland is the latest country to strike a new tariff deal.

Driven by oncology indications, strong growth is on tap for the global market for antibody drug conjugates (ADCs) and the ADC contract manufacturing market. DCAT Value Chain Insights takes an inside look.

Small-molecule and chemically synthesized drugs continue to the dominate new drug approvals by FDA, with about 75% of such approvals in 2025 coming from small-to-medium-sized pharma companies.